Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study

NCT05660135 is registered in ClinicalTrials.gov with Daewoong Pharmaceutical Co. LTD. as lead sponsor.

NCT NCT05660135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05660135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study
Lead sponsor
Daewoong Pharmaceutical Co. LTD.
Phase
Observational
Overall status
Active, not recruiting
Start date
June 20, 2022
Completion date
December 31, 2025
Enrollment
4,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dyslipidemias, hypertension